Eisai Launches Inovelon For Lennox-Gastaut Syndrome In Japan
This article was originally published in PharmAsia News
Executive Summary
Eisai launched Inovelon (rufinamide) for the treatment of Lennox-Gastaut Syndrome, a type of intractable epilepsy that develops from childhood in Japan May 29.